Method for detecting ocln-arhgap26 gene

Abstract

The object of the invention is to elucidate a new causative gene of cancer, polynucleotide, and thereby provide a method for detecting the polynucleotide or a polypeptide that is encoded by the polynucleotide, as well as a primer set or a detection kit for such detection. The detection method detects a fusion gene of a part of an OCLN gene and a part of an ARHGAP26 gene, or a fusion protein encoded by such gene. The primer set includes a sense primer designed from a section encoding OCLN and an antisense primer designed from a section encoding ARHGAP26.

1 - 14 . (canceled) 
     
     
         15 . A method of treating cancer in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a substance for suppressing the expression of a fusion protein of occludin (OCLN) and Rho GTPase activating protein 26 (ARHGAP26), wherein the fusion protein is a polypeptide according to either (1) or (2):
 (1) a polypeptide that comprises an amino acid sequence having no less than 90% identity with an amino acid sequence of SEQ ID NO:2;   (2) a polypeptide that comprises an amino acid sequence of SEQ ID NO:2, or a polypeptide that comprises an amino acid sequence of SEQ ID NO: 2, in which 1 to 10 amino acids are deleted, substituted, inserted and/or added,   thereby treating cancer in the subject.   
     
     
         16 . The method of  claim 15 , wherein the fusion protein is a polypeptide comprising an amino acid sequence having no less than 90% identity with an amino acid sequence of SEQ ID NO:2. 
     
     
         17 . The method of  claim 15 , wherein the fusion protein is a polypeptide comprising an amino acid sequence of SEQ ID NO:2, or the polypeptide comprises an amino acid sequence of SEQ ID NO:2, in which 1 to 10 amino acids are deleted, substituted, inserted and/or added. 
     
     
         18 . The method of  claim 15 , wherein the fusion protein is a polypeptide consisting of an amino acid sequence of SEQ ID NO:2. 
     
     
         19 . The method of  claim 15 , wherein the cancer is treated by inhibiting the growth of cancer cells and/or decreasing the survival of cancer cells in the subject. 
     
     
         20 . The method of  claim 15 , wherein the substance for suppressing the expression of the fusion protein of OCLN and ARHGAP26 is an siRNA targeting ARGHAP26. 
     
     
         21 . The method of  claim 15 , wherein the cancer is stomach cancer.